Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $9.00 price target ...

NASDAQ:IVVD opened at $0.72 on Thursday. Invivyd has a 52 week low of $0.35 and a 52 week high of $4.74. The firm has a market cap of $86.12 million, a price-to-earnings ratio of -0.37 and a beta ...

Reports FY24 revenue $25.3M, consensus $25.15M. “We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million2024 year ...

In this article, we are going to take a look at where Invivyd, Inc. (NASDAQ:IVVD) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in ...

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago. These figures are ...

In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Invivyd (IVVD – Research Report), with a price target of $10.00. The company’s shares closed ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial ...

Detailed price information for Invivyd Inc (IVVD-Q) from The Globe and Mail including charting and trades.